262 related articles for article (PubMed ID: 31592732)
1. MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
Roux A; Roca P; Edjlali M; Sato K; Zanello M; Dezamis E; Gori P; Lion S; Fleury A; Dhermain F; Meder JF; Chrétien F; Lechapt E; Varlet P; Oppenheim C; Pallud J
Radiology; 2019 Dec; 293(3):633-643. PubMed ID: 31592732
[TBL] [Abstract][Full Text] [Related]
2. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
[TBL] [Abstract][Full Text] [Related]
3. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
4. Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
Price SJ; Allinson K; Liu H; Boonzaier NR; Yan JL; Lupson VC; Larkin TJ
Radiology; 2017 Apr; 283(1):215-221. PubMed ID: 27849434
[TBL] [Abstract][Full Text] [Related]
5. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
Park JE; Kim HS; Park SY; Nam SJ; Chun SM; Jo Y; Kim JH
Radiology; 2020 Feb; 294(2):388-397. PubMed ID: 31845844
[TBL] [Abstract][Full Text] [Related]
8. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
[TBL] [Abstract][Full Text] [Related]
9. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
Suh CH; Kim HS; Paik W; Choi C; Ryu KH; Kim D; Woo DC; Park JE; Jung SC; Choi CG; Kim SJ
Radiology; 2019 Jun; 291(3):752-762. PubMed ID: 30990380
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
Li HY; Sun CR; He M; Yin LC; Du HG; Zhang JM
World Neurosurg; 2018 Apr; 112():e407-e414. PubMed ID: 29355809
[TBL] [Abstract][Full Text] [Related]
11. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
[TBL] [Abstract][Full Text] [Related]
12. Radiomic MRI Phenotyping of Glioblastoma: Improving Survival Prediction.
Bae S; Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Radiology; 2018 Dec; 289(3):797-806. PubMed ID: 30277442
[TBL] [Abstract][Full Text] [Related]
13. Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
Patel SH; Batchala PP; Muttikkal TJE; Ferrante SS; Patrie JT; Fadul CE; Schiff D; Lopes MB; Jain R
J Neurooncol; 2021 May; 152(3):523-531. PubMed ID: 33661425
[TBL] [Abstract][Full Text] [Related]
14. Positive influence of partial resection on overall survival of patients with overlapping glioblastomas.
Quick-Weller J; Tritt S; Baumgarten P; Konczalla J; Kashefiolasl S; Noack A; Tichy J; Seifert V; Marquardt G
Clin Neurol Neurosurg; 2017 Oct; 161():22-28. PubMed ID: 28837843
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With
Pallud J; Roux A; Moiraghi A; Aboubakr O; Elia A; Guinard E; Oppenheim C; Tauziede-Espariat A; Parraga E; Gavaret M; Chrètien F; Huberfeld G; Zanello M
Neurology; 2024 Jan; 102(1):e207902. PubMed ID: 38165369
[TBL] [Abstract][Full Text] [Related]
16. Impact of removed tumor volume and location on patient outcome in glioblastoma.
Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
[TBL] [Abstract][Full Text] [Related]
17. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
[TBL] [Abstract][Full Text] [Related]
18. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
19. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
[TBL] [Abstract][Full Text] [Related]
20. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
